A large multicentre analysis of CTGF - 2945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype
(2009) In Annals of the Rheumatic Diseases 68(10). p.1618-1620- Abstract
- Objective: To conduct a replication study to investigate whether the 2945 CTGF genetic variant is associated with systemic sclerosis (SSc) susceptibility or specific SSc phenotype. Methods: The study population comprised 1180 patients with SSc and 1784 healthy controls from seven independent case-control sets of European ancestry (Spanish, French, Dutch, German, British, Swedish and North American). The 2945 CTGF genetic variant was genotyped using a Taqman 59 allelic discrimination assay. Results: An independent association study showed in all the case-control cohorts no association of the CTGF 2945 polymorphism with SSc susceptibility. These findings were confirmed by a meta-analysis giving a pooled OR=1.12 (95% CI 0.99 to 1.25), p=0.06.... (More)
- Objective: To conduct a replication study to investigate whether the 2945 CTGF genetic variant is associated with systemic sclerosis (SSc) susceptibility or specific SSc phenotype. Methods: The study population comprised 1180 patients with SSc and 1784 healthy controls from seven independent case-control sets of European ancestry (Spanish, French, Dutch, German, British, Swedish and North American). The 2945 CTGF genetic variant was genotyped using a Taqman 59 allelic discrimination assay. Results: An independent association study showed in all the case-control cohorts no association of the CTGF 2945 polymorphism with SSc susceptibility. These findings were confirmed by a meta-analysis giving a pooled OR=1.12 (95% CI 0.99 to 1.25), p=0.06. Investigation of the possible contribution of the 2945 CTGF genetic variant to SSc phenotype showed that stratification according to SSc subtypes (limited or diffuse), selective autoantibodies (anti-topoisomerase I or anticentromere) or pulmonary involvement reached no statistically significant skewing. Conclusion: The results do not confirm previous findings and suggest that the CTGF 2945 promoter polymorphism does not play a major role in SSc susceptibility or clinical phenotype. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1492432
- author
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of the Rheumatic Diseases
- volume
- 68
- issue
- 10
- pages
- 1618 - 1620
- publisher
- BMJ Publishing Group
- external identifiers
-
- wos:000269771800018
- scopus:70349386180
- pmid:19054816
- ISSN
- 1468-2060
- DOI
- 10.1136/ard.2008.100180
- language
- English
- LU publication?
- yes
- id
- 79a0370e-ff66-4b44-8321-ee279e0a288d (old id 1492432)
- date added to LUP
- 2016-04-01 13:50:48
- date last changed
- 2022-04-06 07:22:58
@article{79a0370e-ff66-4b44-8321-ee279e0a288d, abstract = {{Objective: To conduct a replication study to investigate whether the 2945 CTGF genetic variant is associated with systemic sclerosis (SSc) susceptibility or specific SSc phenotype. Methods: The study population comprised 1180 patients with SSc and 1784 healthy controls from seven independent case-control sets of European ancestry (Spanish, French, Dutch, German, British, Swedish and North American). The 2945 CTGF genetic variant was genotyped using a Taqman 59 allelic discrimination assay. Results: An independent association study showed in all the case-control cohorts no association of the CTGF 2945 polymorphism with SSc susceptibility. These findings were confirmed by a meta-analysis giving a pooled OR=1.12 (95% CI 0.99 to 1.25), p=0.06. Investigation of the possible contribution of the 2945 CTGF genetic variant to SSc phenotype showed that stratification according to SSc subtypes (limited or diffuse), selective autoantibodies (anti-topoisomerase I or anticentromere) or pulmonary involvement reached no statistically significant skewing. Conclusion: The results do not confirm previous findings and suggest that the CTGF 2945 promoter polymorphism does not play a major role in SSc susceptibility or clinical phenotype.}}, author = {{Rueda, B. and Simeon, C. and Hesselstrand, Roger and Herrick, A. and Worthington, J. and Ortego-Centeno, N. and Riemekasten, G. and Fonollosa, V. and Vonk, M. C. and van den Hoogen, F. H. J. and Sanchez-Roman, J. and Aguirre-Zamorano, M. A. and Garcia-Portales, R. and Pros, A. and Camps, M. T. and Gonzalez-Gay, M. A. and Gonzalez-Escribano, M. F. and Coenen, M. J. and Lambert, N. and Nelson, J. L. and Radstake, T. R. D. J. and Martin, J.}}, issn = {{1468-2060}}, language = {{eng}}, number = {{10}}, pages = {{1618--1620}}, publisher = {{BMJ Publishing Group}}, series = {{Annals of the Rheumatic Diseases}}, title = {{A large multicentre analysis of CTGF - 2945 promoter polymorphism does not confirm association with systemic sclerosis susceptibility or phenotype}}, url = {{http://dx.doi.org/10.1136/ard.2008.100180}}, doi = {{10.1136/ard.2008.100180}}, volume = {{68}}, year = {{2009}}, }